Biosimilar Preferred Drug List (PDL) 2026 Update
This message replaces the former messages sent on November 17, 2025, and November 18, 2025.
Effective January 1, 2026, the Department will add preferred and non-preferred drugs to the Biosimilar PDL.
|
Biosimilar Preferred Drug List 2026 Effective January 1, 2026 |
|
|
Bevacizumab and Biosimilars |
|
|
Preferred Drugs |
Non-Preferred Drugs (PA required) |
|
C9257 - AVASTIN, bevacizumab |
J9035 - AVASTIN, bevacizumab |
|
Q5118 - ZIRABEV, bevacizumab-bvzr |
Q5107 - MVASI, bevacizumab-awwb |
|
Infliximab and Biosimilars |
|
|
Preferred Drugs |
Non-Preferred Drugs (PA required) |
|
Q5121 - AVSOLA, infliximab-axxq |
J1745 - REMICADE, infliximab |
|
Q5104 - RENFLEXIS, infliximab-abda |
Q5103 - INFLECTRA, infliximab-dyyb |
|
Pegfilgrastim and Biosimilars |
|
|
Preferred Drugs |
Non-Preferred Drugs (PA required) |
|
Q5122 - NYVEPRIA, pegfilgrastim-apgf |
J2506 - NEULASTA, pegfilgrastim |
|
Q5108 - FULPHILA, pegfilgrastim-jmdb |
Q5111 - UDENYCA, pegfilgrastim-cbqv |
|
|
Q5120 - ZIEXTENZO, pegfilgrastim-bmez |
|
Rituximab and Biosimilars |
|
|
Preferred Drugs |
Non-Preferred Drugs (PA required) |
|
Q5119 - RUXIENCE, rituximab-pvvr |
J9312 - Rituxan, rituximab |
|
|
Q5123 - Riabni, rituximab-arrx |
|
Q5115 - Truxima, rituximab-abbs |
|
|
Trastuzumab and Biosimilars |
|
|
Preferred Drugs |
Non-Preferred Drugs (PA required) |
|
Q5116 - TRAZIMERA, trastuzumab-qyyp |
J9355 - HERCEPTIN, trastuzumab |
|
|
Q5113 - HERZUMA, trastuzumab-pkrb |
|
Q5117 - KANJINTI, trastuzumab-anns |
|
|
Q5114 - OGIVRI, trastuzumab-dkst |
|
|
Q5112 - ONTRUZANT, trastuzumab-dttb |
|
|
Ustekinumab and Biosimilars |
|
|
Preferred Drugs |
Non-Preferred Drugs (PA required) |
|
Q9996 PYZCHIVA,ustekinumab-ttwe SubQ |
J3357 – STELARA, ustekinumab Subq |
|
Q9997 PYZCHIVA,ustekinumab-ttwe IV |
J3358 – STELARA, ustekinumab IV |
|
Adalimumab and Biosimilars |
|
|
Preferred Drugs and Co-Preferred Drugs |
Non-Preferred Drugs (PA required) |
|
Q5140 - adalimumab-fkjp |
Q5145 – ABRILADA, adalimumab-afzb |
|
J0139 – HUMIRA, adalimumab |
Q5143 – CYTEZLO, adalimumab-adbm |
|
Q5142 -SIMLANDI, adalimumab-ryvk |
Q5144 – IDACIO, adalimumab-aacf |
|
|
Q5141 – YUFLYMA, adalimumab-aaty |
The Biosimilar PDL, implemented in 2022, establishes preferred and non-preferred Physician-Administered Drugs (PADs). Preferred drugs are available without a Prior Authorization (PA). Providers must try preferred drugs first.
Non-preferred drugs require a PA which are available on the Health PAS Online Portal. For the Department to consider approving a non-preferred drug, the provider must include with their PA request documentation of preferred drug failure due to lack of efficacy, intolerable side effects to the preferred drug, or clinical exceptions. Clinical exceptions include the presence of a condition that prevents usage of the preferred drug or a significant drug interaction between another drug and the preferred drug.
For questions, please contact Shannon Beggs, Provider Relations Specialist.